Ligand Pharmaceuticals Incorporated (LGND)

The total asset value of Ligand Pharmaceuticals Incorporated (LGND) stood at $ 942 Mln as on 31-Dec-24

The share price of Ligand Pharmaceuticals Incorporated (LGND) is $108.88 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Ligand Pharmaceuticals Incorporated (LGND) has given a return of 22.09% in the last 3 years.

Ligand Pharmaceuticals Incorporated (LGND) has a market capitalisation of $ 2,093 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.

Since, TTM earnings of Ligand Pharmaceuticals Incorporated (LGND) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ligand Pharmaceuticals Incorporated (LGND) and enter the required number of quantities and click on buy to purchase the shares of Ligand Pharmaceuticals Incorporated (LGND).

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. Address: 555 Heritage Drive, Jupiter, FL, United States, 33458

The CEO & director of Mr. Matthew E. Korenberg. is Ligand Pharmaceuticals Incorporated (LGND), and CFO & Sr. VP is Mr. Matthew E. Korenberg.

There is no promoter pledging in Ligand Pharmaceuticals Incorporated (LGND).

Some of the close peers are:

No, TTM profit after tax of Ligand Pharmaceuticals Incorporated (LGND) was $0 Mln.